ARTICLE | Regulation
Tryngolza expansion gives Ionis its first prevalent-market test
FDA approval moves Tryngolza from rare FCS into severe hypertriglyceridemia, giving Ionis its first shot at a broad cardiometabolic market
June 25, 2026 7:35 PM UTC
A highly anticipated label expansion for triglyceride-lowering therapy Tryngolza olezarsen marks a milestone for Ionis as it completes its transition from discovery engine to integrated biopharma. It also offers a positive case study for new modality companies using rare disease subsets as stepping stones to more prevalent market opportunities.
On Wednesday, FDA approved Tryngolza olezarsen from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to reduce the risk of pancreatitis in patients with severe hypertriglyceridemia, defined as fasting triglyceride levels of at least 500 mg/dL...